Chronic Pain Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Chronic Pain Treatment Market is Segmented By Indication (Neuropathic Pain, Analgesic Infusion, Ablation Devices), By Product Type (Drugs, Devices), By Distribution Channel (Hospital, Clinics, Ambulatory Centers), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Chronic Pain Treatment Market Size

Global Chronic Pain Treatment Market reached US$ 83.8 billion in 2022 and is expected to reach US$ 143.2  billion by 2030 growing with a CAGR of 7.1% during the forecast period 2024-2031. Common types of chronic pain include migraines, back pain, arthritis, neuropathic pain, etc. Chronic pain can also occur after an injury or major surgery. Chronic pain can be treated either by drugs or devices.

Opioids, non-steroidal anti-inflammatory drugs(NSAIDs), anticonvulsants, and antidepressants are the most commonly used drugs for treating chronic pain. Furthermore, significant growth drivers such as the increasing prevalence of chronic diseases, growing geriatric population, technical advancements, rising clinical trials, and increasing FDA approvals give rise to future market growth.

Chronic Pain Treatment Market Scope

To Know More Insights - Download Sample

Chronic Pain Treatment Market Dynamics

Rising FDA Approvals for Neurostimulation Device is Expected to Drive Global Chronic Pain Treatment Market

Increasing advancements in neurostimulation devices are helping those patients who have suffered from chronic neurological disorders. Neurostimulation devices involve the application of electrical stimulation to drive neural function within a circuit. Recent advancements and new product launches are the main factors that give rise to the chronic pain treatment market.

For instance, on March 23, 2023, Neuspera Medical, US-based neuromodulation devices maker has received the US Food and Drug Administration (FDA) approval for its next-generation Neuspera ultra-miniaturized system. The system is designed to deliver peripheral nerve stimulation (PNS) through a wireless, less invasive, and versatile platform compared to commercially available technology.

It is the first PNS device to provide an ultra-miniaturised option to deliver a superior patient experience and enhanced procedural flexibility. This system is used to treat chronic pain disorders and its Neuspera platform is designed to provide new, less invasive, and adaptable treatment options to help patients restore their health and quality of life.

Increasing Clinical Trials for Chronic Back Pain are Expected to Drive Global Chronic Pain Treatment Market

According to ClinicalTrials.gov, on March 9, 2023 Tufts University conducted a clinical trial on the feasibility of immersive virtual reality as a treatment for chronic back pain. The main aim of the study is that the investigators will evaluate the feasibility of Immersive Virtual Reality (IVR) and assess the initial effects of IVR on symptoms, affect, and tolerance to cutaneous stimuli. In this single-arm trial, the investigators will recruit 20 adults with CBP.

Complexities related to Neuropathic Pain are Expected to Hamper Global Chronic Pain Treatment Market Growth

According to an article entitled “Complexity of diagnosis and treatment of neuropathic pain” published on April 23, 2023. A 56 year old woman was diagnosed with Parkinson’s Disease who also had neurological health problems before. According to the anticholinergic scale, the patient presented an AC of 3.25, which can be related to the appearance of adverse effects such as cognitive alterations. As her pain was uncontrollable, she was brought back to the physician to try to achieve an effective treatment. A functional neurological disorder and major depressive disorder were confirmed.

It further states that the treatment of neuropathic pain is complex and accurate diagnosis is important for effective diagnosis. Although, symptomatology often leads to misdiagnosis and treatment with drugs that are not effective in solving the problem and can lead to adverse reactions as in this situation. In these patients, it is necessary to reevaluate the treatment and their cognitive status periodically.

Chronic Pain Treatment Market Segment Analysis

The global chronic pain treatment market is segmented based on product type, indication, distribution channel, and region.

Owing to the Increasing Prevalence of Chronic Diseases like Diabetes, Rising Clinical Trials, the Neuropathic Pain Segment Accounted for Approximately 42.3% of the Chronic Pain Treatment  Market Share

Neuropathic pain refers to chronic pain with shooting and burning sensations. It usually occurs when the central nervous got damaged or malfunctions. Diabetic neuropathy is one of the complications faced by diabetic patients. High blood glucose levels can be one of the factors that cause diabetic neuropathy.

Diabetic neuropathy mainly affects the nerves of the legs and feets. The common symptoms include weakness, numbness, cramps, burning sensation and body aches.  Furthermore, the increasing prevalence of diabetes neuropathy, the rising clinical trials, and rising investment in the drugs are the factors expected to drive the market over the forecast period.

For instance, on July 15, 2022, DyAnsys launched its percutaneous electrical neurostimulator (PENS) device and received U.S FDA approval for ‘First Relief’ device to treat diabetic neuropathic pain. First Relief is intended for symptomatic relief of chronic, intractable pain related to diabetic peripheral neuropathy through multiple treatments for up to 56 days. The device works by placing behind the ear and the wearable device provides continuous pulses of low-level electrical current for several days.

Based on the study, subjects treated with First Relief experienced a significant reduction in VAS pain score from the start of treatment to the end along with the improvements continuing throughout 90 days. Thus, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.

Source: DataM Intelligence Analysis (2023)

Top of Form

Chronic Pain Treatment Market Geographical Share

North America Accounted for Approximately 39.6% of the Market Share in 2022, Owing to the Increasing Research and Development Activities and Well-Established Healthcare Infrastructure 

The North American region is anticipated to experience growth in the field of chronic pain treatments due to factors such as rising research and development efforts, a robust healthcare infrastructure, and supportive reimbursement systems.

These factors contribute to increased accessibility for patients to access advanced therapies, facilitating the adoption of cutting-edge treatments. This trend is expected to drive the North American region's progress in chronic pain treatment throughout the forecast period.

For instance, On Oct 14, 2022, Nevro Corporation announced that the Senza HFX iQ spinal cord stimulation system has received approval from U.S FDA. The system is comprised of the HFX iQ implantable pulse generator (IPG), HFX trial stimulator, charger and HFX app, and will launch with algorithms specifically for treating chronic back and leg pain, including non-surgical back pain (NSBP) and painful diabetic neuropathy (PDN).

Source: DataM Intelligence Analysis (2023)

Chronic Pain Treatment Market Companies

The major global players in the market include Pfizer Inc., Abbott Laboratories, Eli Lilly and Company, Novartis AG, Johnson & Johnson, Sanofi SA, Teva Pharmaceutical Industries Ltd, Baxter International, Merck & Co. Inc, Boston Scientific Corporation among others.

COVID-19 Impact Analysis

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict has had significant implications for various aspects of life in both countries, including healthcare and the management of chronic pain diseases such as arthritis and chronic back pain. The conflict has led to the destruction and disruption of healthcare infrastructure in affected regions. Medical facilities, including hospitals and clinics, may be damaged or inaccessible, making it challenging for patients with chronic pain diseases to receive proper diagnosis, treatment, and follow-up care.

The conflict can result in limited availability of medical resources, including medical devices, medications, and specialized healthcare professionals. This scarcity may lead to delays in diagnosis, inadequate treatment options, and suboptimal disease management for chronic pain disorders patients.

The conflict has resulted in population displacement, with people forced to leave their homes and seek refuge in safer areas. This displacement disrupted patients’ continuity of care, as they may have difficulty accessing their regular healthcare providers and treatment facilities, potentially leading to interruptions in their chronic pain disorder treatment.

By Product Type

• Drugs

• Opioids
• Non- Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Anticonvulsants
• Antidepressants
• Others

• Devices

• Neurostimulation Device
• Analgesic Infusion
• Ablation Devices

By Indication

• Neuropathic Pain
• Arthritis Pain
• Chronic Back Pain
• Cancer
• Migraine
• Others

By Distribution Channel

• Hospitals
• Clinics
• Ambulatory Surgical Centers

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• On May 16 2023, Abbot announced that its spinal cord stimulation (SCS) devices has approved by the U.S Food and Drug Administration. This SCS device is used for the treatment of chronic back pain. It is mainly utilized by people who have not or not eligible to perform surgical back pain. This labeling expansion was supported by results from the distinct study, which demonstrated that Abbott's proprietary BurstDR SCS technology improved pain levels, ability to perform daily activities and emotional well-being in people with chronic back pain.
• On Jan 11 2023, CombiGene entered into a collaboration agreement with Danish Zyneyro regarding the continued development of treatments for chronic pain conditions. The gene therapy company CombiGene’s pipeline consists of CG01, which is being developed for the treatment of drug-resistant epilepsy, and CGT2, which is being developed for the treatment of lipodystrophy. CombiGene also signed an exclusive collaboration and licensing agreement worth up to USD 328.5 million with US-based Spark Therapeutics for the development of CG01.

Why Purchase the Report?

• To visualize the global chronic pain treatment market segmentation based on the product type, indication, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of chronic pain treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global chronic pain treatment market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies